AFR vs Central African Republic: Hepatitis B surface antigen (HBsAg) prevalence
AFR
1.4%
in 2024
Central African Republic
5.3%
in 2024
AFR rank
1st
Central African Republic rank
1st
Hepatitis B surface antigen (HBsAg) prevalence over time
- AFR
- Central African Republic
How they compare
Central African Republic currently reports 5.3% against 1.4% in AFR, a difference of 3.9%.
That makes Central African Republic's figure about 3.8 times AFR's.
Across all 10 years both countries report, Central African Republic has been ahead every year.
AFR ranks 1st and Central African Republic ranks 1st of 13 groups.
Central African Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | AFR | Central African Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.9% | 10.0% | 8.1% | Central African Republic |
| 2020s | 1.6% | 7.0% | 5.4% | Central African Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, AFR or Central African Republic?
- Central African Republic, at 5.3% against 1.4% in AFR as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between AFR and Central African Republic?
- 3.9%, with Central African Republic ahead.
- How many years of comparable data are there for AFR and Central African Republic?
- 10 years are reported by both, from 2015 to 2024.
- How do AFR and Central African Republic rank globally for hepatitis b surface antigen (hbsag) prevalence?
- AFR ranks 1st and Central African Republic ranks 1st of 13 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.